Alnylam Pharmaceuticals Expands Scientific Advisory Board with Dr. Laura Sepp‑Lorenzino

Alnylam Pharmaceuticals Inc. announced that Dr. Laura Sepp‑Lorenzino will join its Scientific Advisory Board (SAB) effective immediately. Dr. Sepp‑Lorenzino, a senior figure in the genetic‑medicine arena, brings a robust track record in both CRISPR‑based gene editing and RNA interference (RNAi) therapeutics.

Professional Background and Relevance to Alnylam

  • Intellia Therapeutics – Chief Scientific Officer; led the transition of CRISPR‑Cas9 gene‑editing platforms from bench to early‑phase human trials, including the first FDA‑approved CRISPR‑derived therapy (Primegen™).
  • Vertex Pharmaceuticals – Head of Genetic Medicine; directed preclinical and Phase I/II programs for cystic fibrosis modulators and liver‑directed therapies, integrating molecular pharmacology with clinical pharmacokinetics.
  • Alnylam (previous collaborations) – Contributed to hepatic infectious‑disease programs, notably the development of the hepatitis B RNAi therapeutic candidate HB‑RNAi‑1, which entered a Phase III study in 2023.

Dr. Sepp‑Lorenzino’s expertise in “translational science”—the conversion of molecular targets into clinically viable products—aligns closely with Alnylam’s mission to expand its RNA‑medicine pipeline beyond the current liver‑centric focus.

Scientific Rationale for the Appointment

Alnylam’s current portfolio includes FDA‑approved drugs such as Onpattro™ (patisiran) and Givlaari™ (givosiran), both targeting hepatic enzymes via siRNA delivery. The company has identified several emerging therapeutic areas requiring advanced delivery systems:

  1. Non‑alcoholic steatohepatitis (NASH) – Early‑phase siRNA candidates are in Phase II trials; however, clinical endpoints such as fibrosis regression remain challenging.
  2. Cardiometabolic diseases – Targeting PCSK9 and ANGPTL3 with lipid‑lowering siRNAs, but requiring sub‑cutaneously optimized formulations.
  3. Oncology – Tumor‑specific delivery of siRNAs to solid tumours remains a regulatory hurdle due to off‑target toxicity concerns.

Dr. Sepp‑Lorenzino’s background in CRISPR editing of hepatic and extra‑hepatic tissues, coupled with her experience in designing delivery vehicles (e.g., lipid nanoparticles, conjugates), will be instrumental in refining these strategies. Her work at Vertex on pharmacokinetic modeling of drug–target engagement will enhance Alnylam’s predictive biomarkers for patient stratification.

Impact on Clinical Development and Regulatory Pathways

  • Clinical Trial Design – Dr. Sepp‑Lorenzino will advise on adaptive trial designs that incorporate real‑time biomarker readouts, potentially reducing the duration of Phase IIb/III studies for NASH and metabolic indications.
  • Regulatory Strategy – Her familiarity with the FDA’s guidance on novel delivery platforms will aid in the preparation of Investigational New Drug (IND) applications, ensuring alignment with the agency’s expectations on safety and efficacy data.
  • Risk‑Benefit Assessment – By integrating CRISPR‑derived safety data with RNAi toxicity profiles, Alnylam can better predict adverse event risks and design mitigations early in development.

Broader Industry Context

The appointment reflects a wider trend in biotechnology whereby companies recruit seasoned scientific leaders into advisory capacities to bridge gaps between molecular innovation and regulatory approval. Such moves:

  • Accelerate Technology Transfer – Senior experts bring proven frameworks for scaling from preclinical models to human trials.
  • Enhance Governance – Robust SABs strengthen scientific oversight, mitigating project risks.
  • Facilitate Cross‑Disciplinary Integration – Leaders with experience across modalities (gene editing, RNAi, small molecules) foster synergistic therapeutic strategies.

Conclusion

Alnylam’s addition of Dr. Sepp‑Lorenzino to its Scientific Advisory Board positions the company to more effectively translate cutting‑edge RNA‑based technologies into clinically approved therapies. While the promise of RNAi and gene‑editing modalities remains high, the objective assessment of clinical data and regulatory pathways will be key to translating this potential into tangible patient benefits. The SAB’s expertise is expected to guide Alnylam through these complex processes, reinforcing the company’s commitment to scientific excellence and commercial success.